Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

  • Macaya, Irati
  • Roman, Marta
  • Welch, Connor
  • Entrialgo-Cadierno, Rodrigo
  • Salmon, Marina
  • Santos, Alba
  • Feliu, Iker
  • Kovalski, Joanna
  • López Erdozain, Inés
  • Rodríguez-Remírez, María
  • Palomino Echeverría, Sara
  • Lonfgren, Shane M.
  • Ferrero, Macarena
  • Calabuig, Silvia
  • Ludwig, Iziar A.
  • Lara-Astiaso, David
  • Jantus-Lewintre, Eloisa
  • Guruceaga, Elizabeth
  • Narayanan, Shruthi
  • Ponz Sarvisé, Mariano
  • Pineda Lucena, Antonio
  • Lecanda, Fernando
  • Ruggero, Davide
  • Khatri, Purvesh
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Ferrer, Irene
  • Paz-Ares, Luis
  • Drosten, Matthias
  • Barbacid, Mariano
  • Gil-Bazo, Ignacio
  • Vicent, Silvestre
Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators or effectors. However, the antitumor effect is highly determined by compensatory mechanisms arising in defined cell types or tumor subgroups. A potential strategy to find drug combinations targeting a larger fraction of KRAS-mutated lung cancers may capitalize on the common, distal gene expression output elicited by oncogenic KRAS. By integrating a signature-driven drug repurposing approach with a pairwise pharmacological screen, here we show synergistic drug combinations consisting of multi-tyrosine kinase PKC inhibitors together with MEK1/2 or KRASG12C inhibitors. Such combinations elicit a cytotoxic response in both in vitro and in vivo models, which in part involves inhibition of the PKC inhibitor target AURKB. Proteome profiling links dysregulation of MYC expression to the effect of both PKC inhibitor-based drug combinations. Furthermore, MYC overexpression appears as a resistance mechanism to MEK1/2 and KRASG12C inhibitors. Our study provides a rational framework for selecting drugs entering combinatorial strategies and unveils MEK1/2- and KRASG12C-based therapies for lung cancer., M.R. was supported by a fellowship from MICIU (FPU15/00173). The Proteomics Platforms of Navarrabiomed led by E.S. and J.F.-I. is a member of Proteored, PRB3 and is supported by grant PT17/0019 of the PE I + D + i 2013¿2016, funded by ISCIII and ERDF. E.J.-L. was supported by Foundation of Spanish Association Against Cancer (PROYE18012ROSE), by Centro de Investigación Biomédica en Red (CIBERONC; CB16-12-00350), and by Generalitat Valenciana (AICO/ 2021/333). F.L. was funded by the Gobierno de Navarra (Ref. 34/2021), the Cancer Research Thematic Network of the Instituto de Salud Carlos III (RTICC RD12/0036/0066), PID2021-122638OB-I00 MCIN/AEI/ 10.13039/501100011033/ FEDER, UE and by FEDER ¿Una manera de hacer Europa¿. I.F. was funded by FIS PI19/00320 and by the Miguel Servet Program CP21/00052. S.V. was supported by Ministerio de Ciencia, Innovación y Universidades, Convocatoria 2019 para incentivar la Incorporación Estable de Doctores (IED2019-001007-I), by FEDER /Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación (SAF2017-89944-R and PID2020¿116344¿RB¿100/MCIN/ AEI/10.13039/501100011033, by a Leonardo Grant for Researchers and Cultural Creators 2018 from BBVA Foundation, by a seed grant at the I Convocatoria Proyectos Prueba de Concepto from PRB3-Proteored (Institute of Health Carlos III-ISCIII), by Fundació La Marató de TV3 (474/ C/2019), and by Foundation of Spanish Association Against Cancer - Strategic Projects 2020 (PROYE20029VICE). M.P.-S. and S.V. were also funded by Fundación Alberto Palatchi.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

  • Marrugal, Ángela
  • Ferrer, Irene
  • Quintanal-Villalonga, Álvaro
  • Ojeda, Laura
  • Pastor, María Dolores
  • García-Luján, Ricardo
  • Carnero, Amancio
  • Paz-Ares, Luis
  • Molina-Pinelo, Sonia
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The use of 90 kDa heat shock protein (HSP90) inhibition as a therapy in lung adenocarcinoma remains limited due to moderate drug efficacy, the emergence of drug resistance, and early tumor recurrence. The main objective of this research is to maximize treatment efficacy in lung adenocarcinoma by identifying key proteins underlying HSP90 inhibition according to molecular background, and to search for potential biomarkers of response to this therapeutic strategy. Inhibition of the HSP90 chaperone was evaluated in different lung adenocarcinoma cell lines representing the most relevant molecular alterations (EGFR mutations, KRAS mutations, or EML4-ALK translocation) and wild-type genes found in each tumor subtype. The proteomic technique iTRAQ was used to identify proteomic profiles and determine which biological pathways are involved in the response to HSP90 inhibition in lung adenocarcinoma. We corroborated the greater efficacy of HSP90 inhibition in EGFR mutated or EML4-ALK translocated cell lines. We identified proteins specifically and significantly deregulated after HSP90 inhibition for each molecular alteration. Two proteins, ADI1 and RRP1, showed independently deregulated molecular patterns. Functional annotation of the altered proteins suggested that apoptosis was the only pathway affected by HSP90 inhibition across all molecular subgroups. The expression of ADI1 and RRP1 could be used to monitor the correct inhibition of HSP90 in lung adenocarcinoma. In addition, proteins such as ASS1, ITCH, or UBE2L3 involved in pathways related to the inhibition of a particular molecular background could be used as potential response biomarkers, thereby improving the efficacy of this therapeutic approach to combat lung adenocarcinoma., I.F. was funded by i + 12 and ISCIII (PI19/00320, CP21/0052) and co-funded by FEDER from Regional Development European Funds (European Union). L.P-A. was funded by the Comunidad de Madrid, CAM, (B2017/BMD3884), AECC (TRNSC18004PAZ), Fundación CRIS contra el cancer (Unidad Integral CRIS de Inmuno-oncología, 2018/0043), ISCIII (PI20/00870; AC20/0070) and CIBERONC (CD16/12/00442), and co-funded by FEDER from Regional Development European Funds (European Union). S.M-P. was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (Nicolás Monardes Program RC-0004-2020 and PECART-0091-2020), and Andalusian Research, Development and Innovation Plan (PY20_00992), ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

  • Cirauqui, Cristina
  • Ojeda, Laura
  • Otano, Itziar
  • Pazos, Irene
  • Santos, Alba
  • Garrido-Martin, Eva M.
  • Yagüe, Patricia
  • Ramos-Paradas, Javier
  • Molina-Pinelo, Sonia
  • Roncador, Giovanna
  • Solórzano, José Luis
  • Muñoz Jiménez, María Teresa
  • Cozar, Patricia
  • Plaza, Patricia
  • Suárez, Rocío
  • Jiménez, Marta
  • Moreno, Roberto
  • Rosado, Arantxa
  • Gámez, Pablo
  • García-Luján, Ricardo
  • Zugazagoitia, Jon
  • Sweet-Cordero, Alejandro
  • Barbacid, Mariano
  • Carnero, Amancio
  • Ferrer, Irene
  • Paz-Ares, Luis
Cristina Cirauqui, Laura Ojeda, Irene Ferrer and Luis Paz-Ares contributed equally to this work., [Rationale] Interleukin-11 (IL-11) has emerged as a significant player in tumourigenesis, with implications across various cancer types. However, its specific role in driving tumour progression in lung adenocarcinoma (LUAD) remains elusive. IL-11's multifaceted impact on both tumour cells and the tumour microenvironment underscores its potential as a therapeutic target in LUAD. This study aims to unravel the involvement of IL-11 in LUAD progression and its influence on the tumour microenvironment., [Methods] Here, we used transcriptomic and digital spatial profiling analyses together with clinic data from two retrospective LUAD patient cohorts. LUAD cell lines genetically engineered to overexpress or to silence IL-11 or its receptor (IL-11RA) were used for in vitro functional analysis and for in vivo experiments. Additionally, we used three different in vivo models: patient-derived xenografts (PDXs), tobacco-exposed mice and genetically engineered mouse models. A neutralising monoclonal antibody against IL-11RA was produced and tested., [Results] Our findings revealed a pivotal role for IL-11 in driving tumourigenesis across various mouse models, highlighting its capacity to modulate tumour immunity towards an immunosuppressive microenvironment. Moreover, we observed a correlation between IL-11 expression and poorer patient outcomes in LUAD. Notably, therapeutic targeting of IL-11RA with a neutralising antibody demonstrated significant anti-tumour efficacy in a PDX model., [Conclusion] The IL-11/IL-11RA axis emerges as a critical driver of LUAD tumourigenesis, exerting its effects through enhanced tumour cell proliferation and remodelling of the tumour microenvironment. Our study highlights the therapeutic potential of disrupting this axis, suggesting that patients exhibiting elevated IL-11 levels may benefit from therapies targeting the IL-11/IL-11RA pathway., We would like to acknowledge patients and their families for donating tumour tissue. We would also like to thank Alicia Maroto Pérez and Carolina Castilla, as well as the Biobank of the Hospital 12 de Octubre and Hospital Virgen del Rocío for kindly providing the samples used in this study. Appreciation is also expressed to Ines Muñoz and Jorge L. Martinez-Torrecuadrada (CNIO) for producing the recombinant human IL-11 and IL-11RA. L.P.-A. was funded by CAM, (B2017/BMD3884, P2022/BMD-7437), Fundación CRIS contra el cancer, CIBERONC (CD16/12/00442) and ISCIII (PI17/00778; PI20/00870; AC20/0070) and I.F. by AECC (AIO2015) and ISCIII (PI16/01311; PI19/00320; CP21/00052) and co-funded by FEDER (European Union). L.O. is funded by the Spanish Ministry of Education (FPU13/02595) and C.C. by ISCIII (CD21/00165). AC was funded by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU), Plan Estatal de I+D+I 2021, Agencia Estatal de Investigación (AEI), Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): ID2021-122629OB-I00 and CIBER de Cáncer (CB16/12/00275). EASC was funded by U01CA199216 from the National Cancer Institute. S.M.-P. was funded by the Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004-2020, and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992) and ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed